Gan & Lee Pharmaceuticals. (SHA:603087)

Market Cap	35.18B +28.2%
Revenue (ttm)	3.85B +30.5%
Net Income	925.74M +59.4%
EPS	1.57 +59.6%
Shares Out	595.20M
PE Ratio	37.56
Forward PE	28.83
Dividend	1.50 (2.61%)
Ex-Dividend Date	n/a

Volume	1,336,074
Average Volume	5,288,260
Open	59.00
Previous Close	59.11
Day's Range	58.72 - 59.88
52-Week Range	40.40 - 82.25
Beta	0.80
RSI	39.51
Earnings Date	Apr 23, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 5,245
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603087

Financial Performance

In 2024, SHA:603087's revenue was 3.05 billion, an increase of 16.77% compared to the previous year's 2.61 billion. Earnings were 614.66 million, an increase of 80.75%.